|Chemical and physical data|
|Molar mass||555.527 g/mol|
|3D model (Jmol)||Interactive image|
Serlopitant (INN, codenamed VPD-737) is a drug which acts as an NK1 receptor antagonist. It was assessed in clinical trials for the treatment of urinary incontinence and overactive bladder, but while it was superior to placebo it provided no advantage over existing approved drugs, and was not approved for further development.
- "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 62" (PDF). World Health Organization. 2009. pp. 261–2. Retrieved 17 November 2016.
- Frenkl, TL; Zhu, H; Reiss, T; Seltzer, O; Rosenberg, E; Green, S (August 2010). "A Multicenter, Double-Blind, Randomized, Placebo Controlled Trial of a Neurokinin-1 Receptor Antagonist for Overactive Bladder". The Journal of Urology. 184 (2): 616–22. doi:10.1016/j.juro.2010.03.147. PMID 20639026.
- Payton, S (August 2010). "Urinary Incontinence: Neurokinin Receptor Antagonist Inferior to Tolterodine for OAB". Nature Reviews Urology. 7 (8): 418. doi:10.1038/nrurol.2010.105. PMID 20726068.